Scalp dysaesthesia and lichen simplex chronicus: diagnostic and therapeutic update with literature review

M. Starace, M. Iorizzo, V. D. Mandel, F. Bruni, C. Misciali, Z. Apalla, T. Silyuk, G. Pellacani, A. Patrizi, B. M. Piraccini and A. Alessandrini

1Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, IRCCS Policlinico di Sant’Orsola, Bologna, Italy; 2Private Dermatology Practice, Lugano and Bellinzona, Switzerland; 3Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Dermatology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; 5Dermatology Department, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece; 6Private Dermatology Practice, Hair Treatment and Transplantation Center, Saint Petersburg, Russia; and 7Dermatologic Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

doi:10.1111/ced.14808

Summary

Scalp dysaesthesia, considered a variant of the cutaneous dysaesthesia syndrome, is characterized by chronic sensory symptoms, including pruritus, pain, burning and stinging in a well-defined location, without objective findings. Its etiology is not well elucidated and treatment options are limited, thus it can be challenging and frustrating for both patient and physician. It can be associated with lichen simplex chronicus. In this paper, we review the literature on the pathogenetic factors, diagnostic methods and therapeutic options in the management of scalp dysaesthesia. Dissociation, cervical spine disease and muscle tension seem to be the most important pathogenetic factors. Trichoscopy, reflectance confocal microscopy and biopsy are all helpful for the diagnosis of the disease. Therapies include high-potency topical or intralesional corticosteroids, capsaicin and topical anaesthetics, sedative antihistamines, tricyclic antidepressants, transcutaneous electric nerve stimulation, botulinum toxin and vitamin B12.

Introduction

Scalp dysaesthesia (SD) is considered a variant of the cutaneous dysaesthesia syndrome, and is characterized by chronic sensory symptoms, including pruritus, pain, burning and stinging in a well-defined location, without objective findings.1,2 The quality of life of patients suffering from SD may be severely affected. There is a marked female predominance, which is remarkable, with a peak age incidence of 35–50 years.

Because the symptoms are localized to the skin, patients often present to dermatologists, and it is therefore important that dermatologists are familiar with this condition and its underlying causes.

Pathogenesis

In terms of pathogenesis, SD has been linked to an underlying psychopathological background or to chronic pain syndrome. Localized radicular neuropathy and abnormal nerve conduction have been shown to be related to SD. Cervical spine involvement,3,4 in which a hyperexcitable state may interfere with pathways descending from an inhibitory centre responsible for pain and pruritus modulation, has also been shown to be associated with SD. While both pain and itch are induced by chemical messengers (histamine, tissue proteases and prostaglandins), there is evidence indicating...
that a unique subpopulation of unmyelinated C nerve fibres are directly activated by pruritus-inducing stimuli. Other potential triggers of SD are stress, hairstyle, heat and seasonality. Psychological stress may directly affect the skin via psychoneuroimmunological reactions due to cutaneous reactivity and sympathetic activation coordinated by the hypothalamic–pituitary–adrenal (HPA) axis. The HPA axis plays a central role in the regulation of epidermal barrier function, cutaneous immune function and cutaneous adnexal and dermal functions, maintaining local and systemic homeostasis.

Psychological stress in patients with SD may be also aggravated by disorders such as cervical spine disease (mostly a degenerative disc disease) and muscle tension due to incorrect posture, resulting in nerve compression, which is correlated with the dermatomal distribution of pruritus. Consequently, the patient’s medical history, habits, social background and environmental factors should be thoroughly investigated to assist in correct diagnosis and appropriate management of this frustrating condition.

Differential diagnoses

Owing to its symptoms, SD is often misinterpreted in the early stages as seborrhoeic dermatitis or red scalp syndrome, with subsequent delayed diagnosis and inadequate treatment. As SD can be intensively pruritic, it can result in subsequent development of lichen simplex chronicus (LSC), which appears as single or multiple, clearly demarcated, thickened and hyperpigmented plaques, with scaling and alopecia due to hair breakage. However, LSC mostly involves the forearms, scrotum and shins, whereas scalp localization is rare. Clinical examination usually reveals single or multiple, irregular, polycyclic or oval-shaped, well-demarcated, thickened and hyperpigmented plaques. Presence of scales and alopecia due to hair breakage are not uncommon. LSC is the result of chronic and repetitive scratching. Scarring is rare, but can be observed in elderly patients.

LSC may be misdiagnosed as trichotillomania, tinea capitis or alopecia areata, but trichoscopy is a useful aid to the differential diagnosis. The typical trichoscopic signs of LSC and their correlation with the corresponding pathological features were described in 2017 by Rakowska et al., and include short hair shafts with split ends that emerge in a group of 2–4 hairs from a single follicular opening, acquiring the aspect of a broom (broom hair), and short hair shafts of the same length with broken tips due to trichorrhexis. In LSC, the skin is also usually thickened and hyperpigmented.

![Figure 1](a) Clinical and (b) trichoscopic (original magnification × 40) features of lichen simplex chronicus, showing short hair shafts with split ends and broom hair. (c,e) Clinical and (d,f) trichoscopic (original magnification × 20) features of (c,d) trichotillomania, showing flame hair, tulip hair and broken hair of different lengths; and (e,f) alopecia areata, showing black dots, dystrophic hair and exclamation-mark hair.
Scalp dysaesthesia and lichen simplex chronicus • M. Starace et al.

Table 1 Suggested treatments for scalp dysaesthesia and lichen simplex chronicus.

| Treatment                  | Dosage                                      |
|----------------------------|---------------------------------------------|
| **Topical**                |                                             |
| Triamcinolone acetonide<sup>a</sup> | 2.5 mg/mL once monthly                       |
| Topical clobetasol<sup>b</sup>   | Once a day                                  |
| Topical capsaicin (cream)   | 0.025–0.1% 3 times daily                      |
| TALK<sup>c</sup>            | Three times daily                           |
| Topical tacrolimus         | 0.1% twice daily                            |
| Topical salicylic acid     | 3–5% twice daily                            |
| Topical gabapentin         | 10% 3 times daily                           |
| **Systemic treatment**     |                                             |
| Anticonvulsants and antidepressants |                                             |
| Pregabalin                 | 50–300 mg daily                             |
| Gabapentin                 | Up to 3000 mg daily                         |
| Mirtazapine                | 15 mg daily                                 |
| Naltrexone                 | 3–5 mg daily                                |
| Amitriptyline              | 10–25 mg daily                              |
| Doxepin                    | Up to 280 mg daily                          |
| Alprazolam                 | Start at 0.25 mg daily                       |
| Lorazepam                  | Start at 1 mg daily                         |
| Sertraline                 | Start at 50 mg daily                         |
| **Antihistamines**         |                                             |
| Bilastine                  | 20–60 mg daily                              |
| Hydroxyzine hydrochloride  | 25–50 mg daily                              |
| Cetirizine                 | 10–30 mg daily                              |
| Levocetirizine             | 5–15 mg daily                               |
| Loratadine                 | 10–30 mg daily                              |
| Fexofenadine               | 60–360 mg daily                             |

<sup>a</sup> Intraleisional injections; <sup>b</sup> cream with or without occlusion; <sup>c</sup> topical amitriptyline 5%, lidocaine 5% and ketamine 10% in Lipobase®. (postinflammatory hyperpigmentation). Trichoscopy allows discrimination between LSC and trichotillomania, in which the short broken hairs are of different lengths, and between LSC and alopecia areata, as the latter is characterized by black dots, dystrophic hair and exclamation-mark hairs<sup>14</sup> (Fig. 1). The short hairs of trichorrhexis nodosa must be differentiated from the Morse code-like hairs typically seen in tinea capitis, in which the multiple, whitish, transverse interruptions along the shaft are due to fungal penetration.<sup>15</sup>

Histopathologically, the trichoscopic signs of LSC correspond to hyperkeratosis of the infundibular ostium, with hair shafts split into two parts by a layer of red blood cells, a feature known as the ‘hamburger sign’. However, this can also be observed in trichotillomania. Typical of LCS is the formation, at the level of the infundibulum, of jagged acanthotic projections that, together with the hair canal in the middle, resemble a ‘gear wheel’ on horizontal sections.<sup>16,17</sup> In the uppermost sections, the epidermis shows thick layers of orthokeratosis and hyperkeratosis. The follicular architecture and the terminal to vellus hair ratio are preserved, with a normal number of terminal follicles, but with a decrease in size and number of sebaceous glands.<sup>16,17</sup>

In a recent paper, we also described the role of reflectance confocal microscopy (RCM) in LSC to facilitate the differential diagnosis between scarring and nonscarring alopecias, biopsy site selection and treatment monitoring.<sup>18</sup> In some cases RCM may be particularly informative, allowing diagnosis without the need of a biopsy.

Management

Management of SD, with or without LSC, is extremely challenging and often frustrating for both patient and clinicians. The goal of treatment is to interrupt the vicious cycle of itching.<sup>19</sup> In the scenario of a neurological trigger of any kind, a neurological consultation is advisable before starting treatment. Supportive counselling, comprising many different psychological interventions may be needed in severe cases. In combination with medical therapy, simple exercises of stretching, once or twice a day, may help to improve cervical nerve compression through the restoration of normal cervical homeostasis.<sup>20</sup>

High-potency topical (with or without occlusion) or intralesional corticosteroids are usually effective, but their prolonged use as maintenance treatment is limited by their well-known adverse effects (AEs).

Topical treatments such as capsaicin in concentrations ranging from 0.025% to 0.1% (with 0.075% reported as optimal), tacrolimus 0.1%, salicylic acid 3–5%, lidocaine and compounds including lidocaine, such as TALK (topical amitriptyline 5%, lidocaine 5% and ketamine 10%) have with slow dose escalation for better tolerance, have been used with satisfactory results.<sup>21,22</sup> Creams and foams are generally better tolerated than lotions. At least twice-daily application is needed but it may take 4–6 weeks for effectiveness.

Systemic treatments include sedative antihistamines as supportive treatment, as they are not sufficient as monotherapy. Low doses of oral pregabalin<sup>23</sup> (up to 300 mg/day), gabapentin (up to 3000 mg/day), mirtazapine (15 mg/day), amitriptyline (10–25 mg/day), doxepin (up to 280 mg/day)<sup>24</sup> and naltrexone (3–5 mg/day) are all possible options, but AEs, especially sedation, hypotension and anticholinergic effects, may limit their use. A list of the possible treatment options is summarized in Table 1.

In addition, transcutaneous electric nerve stimulation<sup>25</sup> and botulinum toxin<sup>26</sup> have been reported to effectively reduce itch, but they are generally reserved for severe or recalcitrant cases and require the
contribution of a neurologist. Supplementation with vitamin B12, if serum levels are < 550 pg/mL, may induce improvement of the SD associated with telogen effluvium, reducing the shedding.\textsuperscript{27–29}

**Conclusion**

Both SD and LSC are challenging conditions in terms of diagnosis and management, mostly due to their vague aetopathogenesis and the lack of well-established treatments. Psychogenic and neurogenic factors play a crucial role and should be thoroughly investigated. Muscular tension in the neck and shoulders (trapezius and sternocleidomastoid muscles) should always be considered as a potential trigger factor for scalp itchy pain and should be treated accordingly in order to improve the overall outcome. In terms of treatment, the potent topical or intraleisional steroids are the first-line choice. Other treatments have less evidence to recommend them, but lack of evidence does not by definition mean lack of efficacy, and so these may have value for patients unresponsive to steroid treatment.

**Acknowledgement**

Open Access Funding provided by Universita degli Studi di Bologna within the CRUI-CARE Agreement. [Correction added on 18 May 2022, after first online publication: CRUI funding statement has been added.]

**Learning points**

- SD is a condition of chronic pain, burning/stinging sensation and/or pruritus of the scalp, in the absence of related skin or systemic disease.
- A neurological and psychological aetiopathogenesis must be investigated, thus referral to a specialist is essential.
- SD may result in LSC, which appears as single or multiple, well-demarcated, thickened and hyperpigmented plaques, with scaling and alopecia due to hair breakage.
- Trichoscopy is fundamental to the diagnosis of LSC, and histopathological confirmation may also be needed.
- Therapy of SD is based on high-potency topical or intraleisonal corticosteroids, capsaicin and topical anaesthetics, sedative antihistamines, tricyclic antidepressants, transcutaneous electric nerve stimulation, botulinum toxin and vitamin B12.

**References**

1. Shumway NK, Cole E, Fernandez KH. Neurocutaneous disease: neurocutaneous dysesthesias. *J Am Acad Dermatol* 2016; 74: 215–28.
2. Hess D, Segal S. Scalp dysesthesia. *Arch Dermatol* 1998; 134: 327–30.
3. Goodkin R, Wingard E, Bernhard JD. Brachioradial pruritus: cervical spine disease and neurogenic/neuropathic pruritus. *J Am Acad Dermatol* 2003; 48: 521–4.
4. Thornsberry LA. English JC III. Scalp dysesthesia related to cervical spine disease. *JAMA Dermatol* 2013; 149: 200–3.
5. Schmelz M, Schmidt R, Bickel A et al. Specific C-receptors for itch in human skin. *J Neurosci* 1997; 17: 8003–8.
6. Gupta MA, Vujcic B, Gupta AK. Dissociation and conversion symptoms in dermatology. *Clin Dermatol* 2017; 35: 267–72.
7. Vázquez-Herrera NE, Sharma D, Aleid NM, Tosti A. Scalp itch: a systematic review. *Skin Appendage Disord* 2018; 4: 187–99.
8. Kinoshita-Ise M, Shear NH. Diagnostic and therapeutic approach to scalp dysesthesia: a case series and published work review. *J Dermatol* 2019; 46: 526–30.
9. Rattanakaemakorn P, Suchonwanit P. Scalp pruritus: review of the pathogenesis, diagnosis, and management. *Biomed Res Int* 2019; 2019: 1268430.
10. Ambika H, Vinod CS, Sushmita J. A case of neurodermatitis circumsctipia of scalp presenting as patchy alopecia. *Int J Trichol* 2014; 5: 94–6.
11. Muylaert BPB, Borgs MT, Michalay AO, Scuotto CRC. Lichen simplex chronicus on the scalp: exuberant clinical, dermoscopic, and histopathological findings. *An Bras Dermatol* 2018; 93: 108–10.
12. Cohen AD, Andrews ID, Medvedovsky E et al. Similarities between neuropathic pruritus sites and lichen simplex chronicus sites. *Isr Med Assoc J* 2014; 16: 88–90.
13. Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of scalp dysesthesia. *Postepy Dermatol Alergol* 2017; 34: 245–7.
14. Alessandrini A, Bruni F, Piraccini BM, Starace M. Common causes of hair loss – clinical manifestations, trichoscopy and therapy. *J Eur Acad Dermatol Venereol* 2020; 35: 629–40.
15. Waskiel-Burnat A, Rakowska A, Sikora M et al. Trichoscopy of tinea capitis: a systematic review. *Dermatol Ther (Heidelb)* 2020; 10: 43–52.
16. Quaresma MV, Marino Alvare AM, Miteva M. Dermoscopic-pathologic correlation of lichen simplex chronicus on the scalp: “broom fibres, gear wheels and hamburgers“. *J Eur Acad Dermatol Venereol* 2016; 30: 343–5.
17. Agrawal S, Dhurat R, Ghate S et al. Lichen simplex chronicus on the scalp: broom fibers on dermoscopy; gear wheel sign and hamburger sign on histopathology. *Indian Dermatol Online J* 2020; 11: 401–3.
18 Starace M, Mandel VD, Bruni F et al. Lichen simplex chronicus of the scalp: dermoscopy and reflectance confocal microscopy features. J Eur Acad Dermatol 2021; 35: e450–2.
19 Koo J, Do JH, Lee CS. Psychodermatology. J Am Acad Dermatol 2000; 43: 848–53.
20 Laider NK, Chan J. Treatment of scalp dysesthesia utilizing simple exercises and stretches: a pilot study. Australas J Dermatol 2018; 59: 318–21.
21 Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 2005; 6: 644–9.
22 Lee HG, Grossman SK, Valdes-Rodriguez R et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability. J Am Acad Dermatol 2017; 76: 760–1.
23 Sarifakioglu E, Onur O. Women with scalp dysesthesia treated with pregabalin. Int J Dermatol 2013; 52: 1398–61.
24 Chan S, Reddy V, Myers B et al. High-dose doxepin for the treatment of chronic, intractable scalp pruritus. JAAD Case Rep 2020; 8: 71–3.

CPD questions

Learning objective
To gain up-to-date knowledge on the features, pathogenesis and diagnosis of scalp dysaesthesia and lichen simplex chronicus.

Question 1
What are the most common symptoms of scalp dysaesthesia (SD)?
(a) Pruritus and erythema.
(b) Burning and pain.
(c) Stinging and pustules.
(d) Blisters and erythema.
(e) Pruritus, burning and stinging.

Question 2
In which of the following groups is scalp dysaesthesia (SD) most frequently seen?
(a) Female patients aged 35–50 years.
(b) Male patients aged 35–50 years.
(c) Female patients aged 50–70 years.
(d) Male patients aged 20–30 years.
(e) Male patients aged 10–19 years.

Question 3
Which of the following is/are the only factor(s) involved in the pathogenesis of scalp dysaesthesia (SD)?
(a) Inflammation of the hair follicle.
(b) Metabolic syndrome.
(c) Psychological stress.
(d) Local trauma.
(e) Abnormal nerve conduction, cervical spine involvement and psychological stress.

Question 4
Which of the following characterizes the trichoscopy feature(s) of lichen simplex chronicus (LSC)?
(a) Patchy hair loss with exclamation-mark hair.
(b) Scarring alopecia with red dots.
(c) Hair loss with demarcated thickened and hyperpigmented plaques, scaling and alopecia due to hair breakage.
(d) Comma hair.
(e) Corkscrew hair.

© 2021 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
Question 5

Which of the following should be considered in the differential diagnosis of lichen simplex chronicus (LSC)?

(a) Telogen effluvium.
(b) Androgenetic alopecia.
(c) Dissecting cellulitis.
(d) Frontal fibrosing alopecia.
(e) Trichotillomania and alopecia areata.

Instructions for answering questions

This learning activity is freely available online at http://www.wileyhealthlearning.com/ced

Users are encouraged to

• Read the article in print or online, paying particular attention to the learning points and any author conflict of interest disclosures.
• Reflect on the article.
• Register or login online at http://www.wileyhealthlearning.com/ced and answer the CPD questions.
• Complete the required evaluation component of the activity.

Once the test is passed, you will receive a certificate and the learning activity can be added to your RCP CPD diary as a self-certified entry.

This activity will be available for CPD credit for 2 years following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional period.